AU2021298186A1 - Pyruvate Kinase Deficiency (PKD) gene editing treatment method - Google Patents

Pyruvate Kinase Deficiency (PKD) gene editing treatment method Download PDF

Info

Publication number
AU2021298186A1
AU2021298186A1 AU2021298186A AU2021298186A AU2021298186A1 AU 2021298186 A1 AU2021298186 A1 AU 2021298186A1 AU 2021298186 A AU2021298186 A AU 2021298186A AU 2021298186 A AU2021298186 A AU 2021298186A AU 2021298186 A1 AU2021298186 A1 AU 2021298186A1
Authority
AU
Australia
Prior art keywords
seq
sequence
gene
homologous
crispr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021298186A
Other languages
English (en)
Inventor
Sara FAÑANAS BAQUERO
Óscar QUINTANA BUSTAMANTE
José Carlos SEGOVIA SANZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro de Investigaciones Energeticas Medioambientales y Tecnologicas CIEMAT
Centro de Investigacion Biomedica en Red CIBER
Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz
Original Assignee
Centro de Investigaciones Energeticas Medioambientales y Tecnologicas CIEMAT
Centro de Investigacion Biomedica en Red CIBER
Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro de Investigaciones Energeticas Medioambientales y Tecnologicas CIEMAT, Centro de Investigacion Biomedica en Red CIBER, Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz filed Critical Centro de Investigaciones Energeticas Medioambientales y Tecnologicas CIEMAT
Publication of AU2021298186A1 publication Critical patent/AU2021298186A1/en
Assigned to FUNDACIÓN INSTITUTO DE INVESTIGACIÓN SANITARIA FUNDACIÓN JIMÉNEZ DÍAZ, CENTRO DE INVESTIGACIONES ENERGÉTICAS, MEDIOAMBIENTALES Y TECNOLÓGICAS, O.A., M.P., CONSORCIO CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED reassignment FUNDACIÓN INSTITUTO DE INVESTIGACIÓN SANITARIA FUNDACIÓN JIMÉNEZ DÍAZ Request for Assignment Assignors: CENTRO DE INVESTIGACIONES ENERGÉTICAS, MEDIOAMBIENTALES Y TECNOLÓGICAS, O.A., M.P., CONSORCIO CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED, FUNDACIÓN INSTITUTO DE INVESTIGACIÓN SANITARIA FUNDACIÓN JIMÉNEZ DÍAZ, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/0104—Pyruvate kinase (2.7.1.40)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021298186A 2020-06-26 2021-06-28 Pyruvate Kinase Deficiency (PKD) gene editing treatment method Pending AU2021298186A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382568.2 2020-06-26
EP20382568.2A EP3929294A1 (en) 2020-06-26 2020-06-26 Pyruvate kinase deficiency (pkd) gene editing treatment method
PCT/EP2021/067719 WO2021260227A1 (en) 2020-06-26 2021-06-28 Pyruvate kinase deficiency (pkd) gene editing treatment method

Publications (1)

Publication Number Publication Date
AU2021298186A1 true AU2021298186A1 (en) 2023-02-09

Family

ID=71607853

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021298186A Pending AU2021298186A1 (en) 2020-06-26 2021-06-28 Pyruvate Kinase Deficiency (PKD) gene editing treatment method

Country Status (9)

Country Link
US (1) US20230303990A1 (https=)
EP (2) EP3929294A1 (https=)
JP (1) JP7847778B2 (https=)
KR (1) KR20230029922A (https=)
CN (1) CN116648511A (https=)
AU (1) AU2021298186A1 (https=)
CA (1) CA3188164A1 (https=)
MX (1) MX2023000035A (https=)
WO (1) WO2021260227A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4534654A1 (en) * 2023-10-02 2025-04-09 Consorcio Centro de Investigación Biomédica en Red Pre-stimulation method of cd34+ cells to achieve clinically relevant gene editing frequencies

Also Published As

Publication number Publication date
MX2023000035A (es) 2023-04-10
WO2021260227A1 (en) 2021-12-30
EP4172332A1 (en) 2023-05-03
JP7847778B2 (ja) 2026-04-20
KR20230029922A (ko) 2023-03-03
JP2023531718A (ja) 2023-07-25
CA3188164A1 (en) 2021-12-30
US20230303990A1 (en) 2023-09-28
CN116648511A (zh) 2023-08-25
EP3929294A1 (en) 2021-12-29

Similar Documents

Publication Publication Date Title
JP7365374B2 (ja) ヌクレアーゼ介在性遺伝子発現調節
JP7844400B2 (ja) 異常ヘモグロビン症の治療用組成物および方法
US12612629B2 (en) Duchenne muscular dystrophy-related exonic splicing enhancer, sgRNA and gene editing tool, and applications
JP7197363B2 (ja) ヌクレアーゼを使用するヒト神経幹細胞のゲノム編集
US20240117352A1 (en) Expression of foxp3 in edited cd34+ cells
AU2013222170B2 (en) Compositions and methods for the treatment of hemoglobinopathies
EP4644567A2 (en) Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
US12497614B2 (en) Compositions and methods for editing beta-globin for treatment of hemaglobinopathies
CA2951882A1 (en) Factor viii mutation repair and tolerance induction and related cdnas, compositions, methods and systems
US20230323322A1 (en) Split cas12 systems and methods of use thereof
US20230303990A1 (en) Pyruvate kinase deficiency (pkd) gene editing treatment method
WO2022221319A2 (en) Methods and compositions for production of genetically modified primary cells
US20240350628A1 (en) Methods for creating regulatory t cells (tregs) using genome engineering

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ SEGOVIA SANZ, JOSE CARLOS; QUINTANA BUSTAMANTE, OSCAR AND FANANAS BAQUERO, SARA

PC1 Assignment before grant (sect. 113)

Owner name: FUNDACION INSTITUTO DE INVESTIGACION SANITARIA FUNDACION JIMENEZ DIAZ

Free format text: FORMER APPLICANT(S): CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED; FUNDACION INSTITUTO DE INVESTIGACION SANITARIA FUNDACION JIMENEZ DIAZ; CENTRO DE INVESTIGACIONES ENERGETICAS, MEDIOAMBIENTALES Y TECNOLOGICAS, O.A., M.P.; THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

Owner name: CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED

Free format text: FORMER APPLICANT(S): CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED; FUNDACION INSTITUTO DE INVESTIGACION SANITARIA FUNDACION JIMENEZ DIAZ; CENTRO DE INVESTIGACIONES ENERGETICAS, MEDIOAMBIENTALES Y TECNOLOGICAS, O.A., M.P.; THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

Owner name: CENTRO DE INVESTIGACIONES ENERGETICAS, MEDIOAMBIENTALES Y TECNOLOGICAS, O.A., M.P.

Free format text: FORMER APPLICANT(S): CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED; FUNDACION INSTITUTO DE INVESTIGACION SANITARIA FUNDACION JIMENEZ DIAZ; CENTRO DE INVESTIGACIONES ENERGETICAS, MEDIOAMBIENTALES Y TECNOLOGICAS, O.A., M.P.; THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY